Screener / SEC EDGAR /CIK 0001048477 /10-K filed Feb 26, 2026, compared with Feb 24, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Biomarin Pharmaceutical Inc BMRN

Compare with peers Embed
What it said it expected, against what it reported

1 target with a reported result

Releases of the last 3 years
Above the range 1 above the last range given
Within the range 0 of 1 range targets
Below the range 0 below the last range given

The numbers BMRN said it expected, in its earnings releases, next to what it then reported for the same period.

Target by target

Each target, with the sentence it came from · release and 10-Q or 10-K

The last range givenReported, abovewithin or keptbelow or missed
TargetWhat the company saidReportedResult
Revenue
Fiscal 2026
Given $3.83B to $3.92B release May 4, 2026
Changed at least $1.00B release Aug 6, 2026
– Not reported yet
The company's words
Increased Full-year 2026 Total Revenues Guidance to between $3.825 billion and $3.925 billion, Representing Accelerated Growth Rate of 20% Y/Y at the Midpoint, and Reflecting the Addition of GALAFOLD ® and POMBILITI ® + OPFOLDA ® to BioMarin’s Portfolio release May 4, 2026
“Strong global demand led us to increase full- year VOXZOGO revenue guidance to at least $1 billion in 2026. release Aug 6, 2026
Diluted EPS (company-defined)
Fiscal 2025 (ended Dec 31, 2025)
Given $4.20 to $4.40 release Feb 19, 2025
Kept $4.20 to $4.40 release May 1, 2025
– No standard number
The company's words
Item 2025 Guidance … Non-GAAP Diluted EPS(2)(3) $4.20 to $4.40 release Feb 19, 2025
Item 2025 Guidance Reaffirmed … Non-GAAP Diluted EPS(2)(3) $4.20 to $4.40 release May 1, 2025
Diluted EPS (company-defined)
Fiscal 2024 (ended Dec 31, 2024)
Given $2.60 to $2.80 release Feb 22, 2024
– No standard number
The company's words
Item 2024 Guidance (in millions, except % and EPS amounts) … Non-GAAP Diluted EPS(2) $2.60 to $2.80 release Feb 22, 2024
Revenue
Fiscal 2024 (ended Dec 31, 2024)
Given $2.70B to $2.80B release Feb 22, 2024
Raised $2.75B to $2.83B release Oct 29, 2024
$2.85B
10-K filed 2025-02-24
Above the range
The company's words
Item 2024 Guidance (in millions, except % and EPS amounts) … Total Revenues $2,700 to $2,800 release Feb 22, 2024
2024 Full-Year Financial Guidance (in millions, except % and EPS amounts) (Updated) … Total Revenues $2,750 to $2,825 release Oct 29, 2024
1 target far from the company's reported total, so not compared (usually a target for one product, segment or definition)
  • Revenue, Fiscal 2025 (ended Dec 31, 2025): said $900.00M to $935.00M, reported $3.22B. The company's words

Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (14 releases since 2024-02-22), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.

Sources

The outlook sentences of each earnings release (8-K item 2.02, exhibit 99), read without AI; results from SEC's XBRL company facts, as first reported.

Also

Earnings releases: each release in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/BMRN/export.csv") into a cell.

Next:Archive
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.